FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).

In June, the FDA issued a Complete Response Letter for Regeneron's aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.

The recommended dose for Eylea HD is 8 mg (0.07 mL of 114.3 mg/mL solution) every four weeks (monthly) for the first three months across all indications, followed by 8 mg every 8 to 16 weeks (2 to 4 months) in wAMD and DME and every 8 to 12 weeks (2 to 3 months) for DR.

The FDA approval is based on the 48-week results of PULSAR and PHOTON – two pivotal trials evaluating Eylea HD compared to Eylea (aflibercept) Injection 2 mg.

Both the PULSAR trial in wAMD (N=1,009) and PHOTON trial in DME (N=658) met their primary endpoint, with Eylea HD demonstrating non-inferior and clinically equivalent vision gains at 48 weeks with both 12- and 16-week dosing regimens after only three initial monthly doses, compared to an Eylea 8-week dosing regimen after initial monthly doses.

Regeneron and Bayer AG (OTC:BAYRY) (OTC:BAYZF) are jointly developing Eylea HD.

Eylea HD is priced at $2,625 per single-use vial in the U.S.

Price Action: REGN shares closed at $812.40 on Friday.

Now Read: Elon Musk Issues Grim Outlook On X, Shares 'Sad Truth' About Social Media Platforms

REGNRegeneron Pharmaceuticals Inc

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.